Focus booster app cnet1/4/2023 Agreements with both vaccine companies would open up millions more doses, but this "can only be exercised" with more funding from Congress. The US has also secured a previous order of 105 million doses of Pfizer, but that isn't enough for all people in the US, the HHS said in the press release. The US Department of Health and Human Services on July 29 announced that it had ordered 66 million doses of Moderna's bivalent booster candidate, purchased with reallocated money meant for other COVID-19 resources as health officials have failed to secure more funding from Congress. (Novavax targets the older COVID-19 strains and isn't available as a booster yet for people who've been vaccinated.) (Only adults 50 and older and younger immunocompromised people are eligible for a second booster.) It also comes as Novavax, the newest COVID-19 vaccine to make the US market, won a recommendation from the CDC and FDA that allows it to be given to kids and teens as young as 12 as a primary series. The pressure on the timeline to come up with a new vaccine comes partly from talk about expanding the eligibility of who can get a second booster of the currently available vaccines. BA.5 makes up the majority of current COVID-19 cases. The FDA asked for boosters focusing on BA.4/BA.5 in June, in addition to the older strain of the virus, in an effort to keep up with the ever-evolving coronavirus. Moderna's announcement followed Pfizer and BioNTech's own ask of the FDA one day earlier for another booster candidate that targets the newer versions of omicron. If authorized, Moderna said it could deliver doses in September. Moderna announced Tuesday that it's submitted an application to the FDA for emergency use authorization of its new booster candidate targeting the BA.4/BA.5 variants of COVID-19. Pfizer and Moderna have submitted applications to the US Food and Drug administration for updated COVID-19 boosters that target omicron. The older vaccine formulas are still effective at preventing severe disease, but the mutating virus is whittling some of that protection away.īefore vaccines start rolling out to the public this fall, the FDA and CDC need to sign off. Why it mattersĬOVID-19 is still making people sick and leading to hospitalizations and deaths. The FDA is reviewing COVID boosters from Pfizer and Moderna that target the BA.5 subvariant.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |